Business context and reporting period
The filing is Onconova Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020. The request metadata names Traws Pharma, Inc.; that does not match the registrant identified in the filing and should be verified. Onconova is a clinical-stage oncology biopharmaceutical company, focused principally on rigosertib.
Financial performance and position
| Metric | Q2 2020 / June 30, 2020 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $56,000 for Q2; $108,000 for first half | $2.022 million for Q2 2019; $2.090 million for first half 2019 |
| Operating expenses | $7.395 million for Q2; $12.572 million for first half | $5.655 million and $12.963 million, respectively |
| Net loss | $7.395 million for Q2; $12.487 million for first half | $3.561 million and $11.161 million, respectively |
| Operating cash flow | Cash used of $11.844 million in the first half | Cash used of $11.510 million in first half 2019 |
| Cash and cash equivalents | $27.228 million | $22.726 million at December 31, 2019 |
| Working capital | $19.2 million | Not stated as a comparable figure in the filing text |
| Total liabilities | $12.566 million; includes $232,000 warrant liability | $12.100 million at December 31, 2019 |
The company reported no meaningful product-sales revenue; reported revenue principally reflects license and collaboration arrangements. The filing does not identify interest-bearing debt. It reported a $415.886 million accumulated deficit at quarter-end. Profit margins are not meaningful given the company’s minimal revenue and ongoing development-stage losses.
Material changes versus prior comparable periods
- Q2 revenue fell 97% year over year, primarily because the 2019 quarter included revenue from the HanX rigosertib transaction. The HanX agreement was deemed void ab initio in January 2020 after HanX failed to meet its obligations.
- Q2 operating expenses increased $1.740 million year over year: G&A rose $834,000 and R&D rose $906,000. Management cited commercialization preparation, annual-meeting and related legal/consulting costs, clinical-supply manufacturing, and regulatory consulting.
- First-half operating expenses decreased $391,000, while net loss increased $1.326 million, reflecting the sharp revenue decline. The lower year-over-year G&A included the absence of 2019 severance and accelerated stock-option vesting costs.
- First-half financing provided $16.360 million, mainly from the January stock offering and warrant exercises. Cash increased $4.502 million over the first half despite operating cash use.
- Common shares outstanding increased from 111.2 million at December 31, 2019 to 174.2 million at June 30, 2020. The filing reports 179.7 million outstanding on August 3, 2020.
Outlook, commentary, risks and unusual items
- Management estimated that June 30 cash would fund operations and ongoing trials into the fourth quarter of 2021. It also said substantial additional financing is needed, with no assurance of obtaining it on acceptable terms or at all; without funding, the company may delay, scale back or eliminate programs and could face going-concern risk.
- The Phase 3 INSPIRE trial completed enrollment of 360 patients in March 2020. The required survival events had been reached by July, and management anticipated topline survival data in Q3 2020. The company noted that further development plans and costs depend on trial results and regulatory discussions.
- Management anticipated a U.S. IND filing for ON 123300 in Q4 2020. Its Chinese IND had been approved in January 2020. The filing also describes planned or ongoing rigosertib studies, while noting that several programs require additional funding.
- COVID-19 could disrupt patient enrollment, clinical-site operations, manufacturing and supplies, regulatory timelines, and access to capital. Management said studies had been affected to differing extents.
- On August 3, 2020, Nasdaq notified the company it had regained compliance with the minimum bid-price requirement. The filing cautions that future listing compliance is not assured.
- After quarter-end, 9.4 million warrants were exercised through August 12, generating $2.5 million. The company also approved cash-settled employee SAR and PSU awards in July; the filing states no awards had vested as of August 12 and no liability estimate was then possible.
- The company reported no pending material legal proceedings. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported for the quarter.
Important facts for investors to verify
- Confirm that the intended filing is Onconova Therapeutics, Inc., not Traws Pharma, Inc.
- Check the actual INSPIRE topline survival results and subsequent regulatory plans against management’s Q3 2020 expectation.
- Assess the cash runway and financing requirement, including subsequent warrant exercises, future dilution, and whether new funding was secured.
- Review ongoing COVID-19 effects, Nasdaq listing status, and any eventual expense or liability from the cash-settled awards.